LitAlert ~~ GeneLit.com

    • Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial.
    • Mirza MR, Benigno B, Dørum A, Mahner S, Bessette P, Bover Barceló I, Berton-Rigaud D, Ledermann JA, Rimel BJ, Herrstedt J, Lau S, du Bois A, Casado Herráez A, Kalbacher E, Buscema J, Lorusso D, Vergote I, Levy T, Wang P, de Jong FA, Gupta D, Matulonis UA.
    • Gynecol Oncol. 2020 Sep 24:S0090-8258(20)33899-3. doi: 10.1016/j.ygyno.2020.09.006. Epub ahead of print.
    • The effect of the triazene compound CT913 on ovarian cancer cells in vitro and its synergistic interaction with the PARP-inhibitor olaparib.
    • Wichmann C, Klotz DM, Zeiler HJ, Hilger RA, Grützmann K, Krüger A, Aust D, Wimberger P, Kuhlmann JD.
    • Gynecol Oncol. 2020 Sep 24:S0090-8258(20)33911-1. doi: 10.1016/j.ygyno.2020.09.018. Epub ahead of print.
    • Who Should Consider BRCA Testing?
    • [No author given]
    • My Gene Counsel. Genetic Journal Blog. 2020 Sep 24.